全文获取类型
收费全文 | 97358篇 |
免费 | 9447篇 |
国内免费 | 5725篇 |
专业分类
耳鼻咽喉 | 113篇 |
儿科学 | 4057篇 |
妇产科学 | 388篇 |
基础医学 | 7724篇 |
口腔科学 | 527篇 |
临床医学 | 8616篇 |
内科学 | 24669篇 |
皮肤病学 | 626篇 |
神经病学 | 1534篇 |
特种医学 | 3255篇 |
外国民族医学 | 20篇 |
外科学 | 24863篇 |
综合类 | 15093篇 |
现状与发展 | 31篇 |
一般理论 | 2篇 |
预防医学 | 3060篇 |
眼科学 | 1285篇 |
药学 | 6968篇 |
42篇 | |
中国医学 | 4609篇 |
肿瘤学 | 5048篇 |
出版年
2024年 | 265篇 |
2023年 | 1795篇 |
2022年 | 2733篇 |
2021年 | 3836篇 |
2020年 | 3933篇 |
2019年 | 3649篇 |
2018年 | 3658篇 |
2017年 | 3744篇 |
2016年 | 4111篇 |
2015年 | 3780篇 |
2014年 | 6129篇 |
2013年 | 6436篇 |
2012年 | 5169篇 |
2011年 | 6076篇 |
2010年 | 5032篇 |
2009年 | 4998篇 |
2008年 | 5109篇 |
2007年 | 5323篇 |
2006年 | 5238篇 |
2005年 | 4531篇 |
2004年 | 3663篇 |
2003年 | 3157篇 |
2002年 | 2665篇 |
2001年 | 2352篇 |
2000年 | 1983篇 |
1999年 | 1581篇 |
1998年 | 1466篇 |
1997年 | 1280篇 |
1996年 | 1176篇 |
1995年 | 979篇 |
1994年 | 1029篇 |
1993年 | 693篇 |
1992年 | 788篇 |
1991年 | 582篇 |
1990年 | 474篇 |
1989年 | 424篇 |
1988年 | 404篇 |
1987年 | 306篇 |
1986年 | 258篇 |
1985年 | 296篇 |
1984年 | 243篇 |
1983年 | 151篇 |
1982年 | 187篇 |
1981年 | 157篇 |
1980年 | 129篇 |
1979年 | 110篇 |
1978年 | 110篇 |
1977年 | 89篇 |
1976年 | 100篇 |
1975年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
23.
Yesim Aydinok 《ISBT科学丛刊》2020,15(1):102-109
Lifetime red cell concentrate (RCC) transfusions still account for significant iron overload‐related morbidity and mortality despite chelation therapy in thalassaemia. The cumulative risk of transfusion‐transmitted infections is substantial for thalassaemia patients. Pathogen reduction technologies for RCC may imply a proactive approach against new/re‐emerging pathogens and may be an ultimate safeguard for transfusion safety in the developing countries. Red cell alloimmunization may become a significant clinical challenge in thalassaemia. The availability of high‐throughput molecular blood group antigen typing in the donors may allow perfect match transfusion, beyond ABO‐D and CEK antigen‐matched transfusions. Allogeneic stem cell transplantation (A‐SCT) is the only available curative therapy in thalassaemia, but carries a substantial risk of serious adverse events and mortality. Gene addition therapy for correction of the α‐globin chain imbalance overcomes the problems of donor availability and immunological complications of A‐SCT. Gene editing by either gene disruption or correction emerged as a potential alternative to gene addition therapy in beta‐thalassaemia. A new era of novel therapeutics targeting α/β imbalance, ineffective erythropoiesis or iron dysregulation is unfolding in thalassaemia management, and a number of those now have agents in preclinical and clinical development. Hydroxyurea (HU) may improve globin chain imbalance and be beneficial for reducing or omitting transfusion requirement. Ruxolitinib has allowed steady decrease in spleen volume that may serve for avoiding splenectomy in beta‐thalassaemia. Luspatercept may restore normal erythroid differentiation and improve anaemia. Hepcidin mimetics or TMPRSS6 inhibitors may modulate ineffective erythropoiesis by iron restriction and improve anaemia and organ iron loading. 相似文献
24.
25.
目的探讨足趾移植长手指全形再造手术的临床疗效。方法自2015年6月至2019年6月,对16例因外伤致手指缺损患者采用足趾移植长手指全形再造术,术后评估供区及受区的感觉功能、运动功能及外观形态,分析指甲畸形及增生性瘢痕的发生情况,并记录术后发生感染、血肿、皮片坏死及供区愈合不良等情况;通过调查问卷的方式分析患者的满意度。结果所有患者术后获随访1~12个月,其中2例受区发生感染,1例受区皮片边缘发生坏死,经换药后予以缓解;其余患者的供、受区均未出现长时间的痛疼感觉,受区感觉功能恢复达87.50%,受区运动功能恢复均较满意,手指外形基本满意。供区感觉受影响者2例,运动功能受限者1例,外形一般者2例。所有患者无指甲畸形及增生性瘢痕发生;满意者1例,基本满意者14例,不满意者1例。结论采用足趾移植长手指全形再造手术,基本可以满足患者及医师对于缺损手指进行完美修复的目标。 相似文献
26.
新型冠状病毒肺炎(新冠肺炎)对人民的生命健康造成了巨大的威胁。在新冠肺炎疫情下,如何应对肝胆外科肝癌患者的门诊筛查、病房管理以及安全地实施肝癌手术,都是对肝胆外科医师提出的新挑战。我们认为,该病的临床处置应在筛查新冠肺炎的前提下,遵循正规操作流程,做好充分防护。对于需要急诊治疗但无法排除新冠肺炎的肝癌患者,须综合考虑患者的病情严重程度、手术方式及手术室条件,慎重制定个体化治疗方案。整个诊疗过程必须遵从既保证患者的安全及疗效,又要降低医护人员感染风险的原则。 相似文献
27.
Rafiye Ciftciler Haluk Demiroglu Yahya Buyukasık Elifcan Aladag Salih Aksu Ibrahim C. Haznedaroglu Nilgun Sayınalp Osman Ozcebe Umit Yavuz Malkan Hakan Goker 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):177-182
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献28.
《Journal of the American College of Surgeons》2020,230(4):363-370
- Download : Download high-res image (207KB)
- Download : Download full-size image
29.
30.